Decoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer.
Summary
This study investigates how altered enhancers in prostate cancer cooperate within the 3D chromatin architecture to drive oncogenic programs. Researchers identified prostate cancer-specific enhancers that form highly nested interactions with promoters, coalescing into multi-connected hubs. CRISPR/Cas9 perturbations distinguished distinct enhancer classes: central enhancers, whose deletion collapses hub-wide activity and impairs cell proliferation, and redundant enhancers, whose deletion has minimal impact due to compensatory architectural rewiring. The transcription factor FOXA1 was found to directly bind and regulate these distinct enhancer classes. These findings suggest that enhancers function in a coordinated manner and open new avenues for precision therapies.
Analysis
The study uncovered the existence of multi-connected, prostate cancer-specific chromatin interaction hubs formed by enhancers. It distinguished distinct enhancer classes (central and redundant) with hierarchical roles in gene regulation, where central enhancers are critical for cell survival and redundant ones can be compensated. The transcription factor FOXA1 was identified as a key regulator of these enhancers. The integration of 201 H3K27ac ChIP-seq datasets enabled enhancer identification, while ultra-high-resolution Region Capture Micro-C was crucial for profiling 3D chromatin interactions, and CRISPR/Cas9 perturbations were used for functional characterization of the different enhancer classes. These findings provide a deeper understanding of the epigenetic mechanisms in prostate cancer. The ability to modulate gene expression in a cell-type specific manner, by targeting these hubs or specific enhancer classes, could lead to the development of novel precision therapies. For instance, strategies aimed at disrupting central enhancer activity or FOXA1's interaction with these elements could be explored for future clinical applications, potentially within a 5+ year timeframe for drug development.